AstraZeneca seeking to get cancer drugs to patients early - (The Telegraph via NewsPoints Desk)

  • AstraZeneca hopes to launch its experimental lung cancer therapies AZD9291 and MEDI4736 in the UK using the recently launched early access to medicines scheme, The Telegraph reported Monday.
  • "Now we are looking at how we give patients early access to [AZD9291] and [MEDI4736] around the world," stated AstraZeneca CEO Pascal Soriot, adding "we are looking at plans on a country-by-country basis."
  • AstraZeneca has highlighted its oncology pipeline at the ASCO annual meeting after resisting a nearly 70-billion-pound takeover approach from Pfizer.
  • At the meeting, the British company disclosed that AZD9291 reduced tumour size in 65 percent of patients, while data on MEDI4736 are anticipated at the meeting.
  • Meanwhile, the drugmaker said that its experimental ovarian cancer olaparib and cedinarib extended survival by 18 months, versus nine months of olaparib alone.
  • Regarding Pfizer's takeover offer, Soriot noted that he "never said a merger is bad" but believes that AstraZeneca "doesn't need a merger."

To read more NewsPoints articles, click here.